Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial
Titel:
Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial
Auteur:
Querfeld, Christiane Thompson, John A. Taylor, Matthew Pillai, Raju Johnson, Lisa DS. Catalano, Tina Petrova, Penka S. Uger, Bob A. Irwin, Meghan Thompson, Theresa Sievers, Eric L. Akilov, Oleg